Gonadal dysgenesis
Gonadal dysgenesis is classified as any congenital developmental disorder of the reproductive system[1] in the male or female. It is the atypical development of the gonads in an embryo,[2] with reproductive tissue replaced with functionless, fibrous tissue, termed streak gonads.[3] Streak gonads are a form of aplasia, resulting in hormonal failure that manifests as sexual infantism and infertility, with no initiation of puberty and secondary sex characteristics.[4]
Gonadal dysgenesis | |
---|---|
Specialty | Medical genetics |
Diagnostic method | pelvic examination (checking for maturation of external internal genitals),general examination(looking for secondary sexual characters), chromosome karyotyping, hormone levels like FSH ,LH (which are increased in case of purely xx dysgenesis) |
Gonadal development is a genetically controlled process by the chromosomal sex (XX or XY) which directs the formation of the gonad (ovary or testis).[4]
Differentiation of the gonads requires a tightly regulated cascade of genetic, molecular and morphogenic events.[5] At the formation of the developed gonad, steroid production influences local and distant receptors for continued morphological and biochemical changes.[5] This results in the appropriate phenotype corresponding to the karyotype (46,XX for females and 46,XY for males).[5]
Gonadal dysgenesis arises from the failure of signalling in this tightly regulated process during early foetal development.[6][7]
Manifestations of gonadal dysgenesis are dependent on the aetiology and severity of the underlying defect.[7]
Causes
- Pure gonadal dysgenesis 46,XX also known as XX gonadal dysgenesis
- Pure gonadal dysgenesis 46,XY also known as XY gonadal dysgenesis
- Mixed gonadal dysgenesis also known as partial gonadal dysgenesis, and 45,X/46,XY mosaicism
- Turner syndrome also known as 45,X or 45,X0
- Endocrine disruptions
Pathogenesis
46,XX Gonadal Dysgenesis
46,XX gonadal dysgenesis is characteristic of female hypogonadism with a karyotype of 46,XX. [8] Streak ovaries are present with non-functional tissues unable to produce the required sex steroid oestrogen [9] Low levels of oestrogen effect the HPG axis with no feedback to the anterior pituitary to inhibit the secretion of FSH and LH.[9] FSH and LH are secreted at abnormal elevated levels.[9] Improper levels of these hormones will cause a failure to initiate puberty, undergo menarche, and develop secondary sex characteristics.[9][10] If sufficient functional ovarian tissue is present, limited menstrual cycles can occur.[9]
The pathogenesis of 46,XX gonadal dysgenesis is unclear, as it can manifest from a variety of dysregulations.[6] Interruption during ovarian development in embryogenesis can cause 46,XX gonadal dysgenesis with cases of abnormalities in the FSH receptor[10][11] and mutations in steroidogenic acute regulatory protein (StAR protein) which regulates steroid hormone production.[10]
46,XY Gonadal Dysgenesis
46,XY gonadal dysgenesis is characteristic of male hypogonadism with karyotype 46,XY.[12]
In embryogenesis, the development of the male gonads is controlled by the testis determining factor located on the sex-determining region of the Y chromosome (SRY).[12] The male gonad is dependent on SRY and the signalling pathways initiated to several other genes to facilitate testis development.[9]
The aetiology of 46,XY gonadal dysgenesis can be caused by mutations in the genes involved in testis development such as SRY, SOX9, WT1, SF1, and DHH.[9][13] If a single or combination of these genes are mutated or deleted, downstream signalling is disrupted, leading to malformation of male external genitalia.[14]
SRY acts on gene SOX9 which drives Sertoli cell formation and testis differentiation.[15] An absence in SRY causes SOX9 to not be expressed at the appropriate time or concentration, leading to a deficiency in testosterone and Anti-Müllerian hormone production.[4] Inadequate levels of testosterone and Anti-Müllerian hormone disrupts the development of Wolffian ducts and internal genitalia that are key to male reproductive tract development.[4] The lack of the male associated steroid hormones drives Müllerian duct development and promotes the development of female genitalia.[12]
Gonadal streaks replace the tissues of the testes, resembling ovarian stroma absent of follicles.[14] 46,XY gonadal dysgenesis can remain unsuspected until delayed pubertal development is observed.[14]
Approximately 15% of cases of 46,XY gonadal dysgenesis carry de novo mutations in the SRY gene,[16] with an unknown causation for the remaining portion of 46,XY gonadal dysgenesis patients.[15]
Mixed Gonadal Dysgenesis
Mixed gonadal dysgenesis, also known as X0/XY mosaicism or partial gonadal dysgenesis[15] is a sex development disorder associated with sex chromosome aneuploidy and mosaicism of the Y chromosome.[14] Mixed gonadal dysgenesis is the presence of two or more germ line cells.[17]
The degree of development of the male reproductive tract is determined by the ratio of germ line cells expressing the XY genotype.[15][17]
Manifestations of mixed gonadal dysgenesis are highly variable with asymmetry in gonadal development of testis and streak gonad, accounted for by the percentage of cells expressing XY genotype.[16][17] The dysgenic testis can have adequate functional tissue to produce satisfactory levels of testosterone to cause masculinisation.[16][17]
Mixed gonadal dysgenesis is poorly understood at the molecular level.[17] The loss of the Y chromosome can occur from deletions, translocations, or migration failure of paired chromosomes during cell division.[16][17] The chromosomal loss results in partial expression of the SRY gene, giving rise to abnormal development of the reproductive tract and altered hormones levels.[16][17]
Turner syndrome
Turner syndrome, also known as 45,X or 45,X0, is a chromosomal abnormality characterised by a partial or completely missing second X chromosome[4][18][19] giving a chromosomal count of 45, instead of the correct count of 46 chromosomes.[18]
Dysregulation in meiosis signalling to germ cells during embryogenesis may result in nondisjunction and monosomy X from separation failure of chromosomes in either the parental gamete or during early embryonic divisions.[4][7]
The aetiology of Turner syndrome phenotype can be the result of haploinsufficiency, where a portion of critical genes are rendered inactive during embryogenesis.[4][18] Normal ovarian development requires these vital regions of the X chromosome that are inactivated.[4][20] Clinical manifestation include primary amenorrhea, hypergonadotropic hypogonadism, streak gonads, infertility and failure to develop secondary sex characteristics.[19] Turner Syndrome is not diagnosed until a delayed onset of puberty with Müllerian structures found to be in infantile stage.[4] Physical phenotypic characteristics include short stature, dysmorphic features and lymphedema at birth.[17] Comorbidities include heart defects, vision and hearing problems, diabetes and low thyroid hormone production.[4][19]
Endocrine Disruptions
Endocrine disruptors interfere with the endocrine system and hormones.[21] Hormones are critical for the correct events in embryogenesis to occur.[20] Foetal development relies on the proper timing of the delivery of hormones for cellular differentiation and maturation.[4] Disruptions can cause sexual development disorders leading to gonadal dysgenesis.[22]
History
Turner syndrome was first described independently by Otto Ulrich in 1930 and Henry Turner in 1938.[23] 46,XX pure gonadal dysgenesis was first reported in 1960.[23] 46,XY pure gonadal dysgenesis, also known as Swyer syndrome, was first described by Gim Swyer in 1955.[23]
References
- Carreau S, Lejeune H (2001). "Andrology: Male Reproductive Health and Dysfunction". Andrologie. 11 (2): 95–97. doi:10.1007/BF03034401.
- Hughes I (2008). "The Testes: Disorders of Sexual Differentiation and Puberty in the Male". Pediatric Endocrinology. Canadian Medical Association Journal. 135. Elsevier Health Sciences. pp. 662–685. doi:10.1016/B978-1-4160-4090-3.X5001-7. ISBN 9781416040903. PMC 1491552.
- "Gonadal Streak. Farlex Partner Medical Dictionary".
- Balsamo A, Buonocore G, Bracci R, Weindling M (2012). "Disorders of Sexual Development". Neonatology. Springer.
- Pieretti RV, Donahoe PK (2018). "Pathogenesis and Treatment of Disorders of Sexual Development". Endocrine Surgery in Children. Springer. pp. 241–270. doi:10.1007/978-3-662-54256-9_18. ISBN 978-3-662-54254-5.
- Boizet-Bonhoure B (2015). "Development and Pathology of the Gonad". Seminars in Cell & Developmental Biology. 45: 57–58. doi:10.1016/j.semcdb.2015.11.009. PMID 26653403.
- Jorgensen A, Johansen M, Juul A, Skakkebaek N, Main K, Rajpert-De Meyts E (2015). "Pathogenesis of germ cell neoplasia in testicular dysgenesis and disorders of sex development". Seminars in Cell & Developmental Biology. 45: 124–137. doi:10.1016/j.semcdb.2015.09.013. PMID 26410164.
- Quayle S, Copeland K (1991). "46, XX Gonadal Dysgenesis With Epibulbar Dermoid". American Journal of Medical Genetics. 40 (1): 4075–4076. doi:10.1002/ajmg.1320400114. PMID 1909490.
- Nieschlag E, Behre H, Wieacker P, Meschede D, Kamischke A, Kliesch S (2010). "Disorders at the Testicular Level". Andrology. Springer. pp. 193–238. doi:10.1007/978-3-540-78355-8_13. ISBN 978-3-540-78355-8.
- Grimbly C, Caluseriu O, Metcalfe P, Jetha M, Rosolowsky E (2016). "46, XY disorder of sex development due to 17-beta hydroxysteroid dehydrogenase type 3 deficiency: a plea for timely genetic testing". International Journal of Pediatric Endocrinology. 12: 12. doi:10.1186/s13633-016-0030-x. PMC 4908721. PMID 27307783.
- Aittomaki K, Lucena J, Pakarinen P, Sistonen P, Tapanainen J, Gromoll J, Kaskikari R, Sankila E (1995). "Mutations in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure". Cell. 82 (6): 959–968. doi:10.1016/0092-8674(95)90275-9. PMID 7553856. S2CID 14748261.
- Chen H, Huang H, Chang T, Lai C, Soong Y (2006). "Pure XY gonadal dysgenesis and agenesis in monozygotic twins". Fertility and Sterility. 85 (4): 1059.9–1059.11. doi:10.1016/j.fertnstert.2005.09.054. PMID 16580399.
- Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura E, Eskin A, Bramble M, Arboleda V, Bazter R, Neslon S, Delot E, Harley V, Vilain E (2018). "Identification of novel candidate genes for 46, XY disorders of sex development (DSD) using a C57BL/6J-Y POS mouse model". Biology of Sex Differences. 9 (8): 8. doi:10.1186/s13293-018-0167-9. PMC 5789682. PMID 29378665.
- Han Y, Wang Y, Li Q, Dai S, He A, Wang E (2011). "Dysgerminoma in a case of 46, XY pure gonadal dysgenesis (Swyer Syndrome): a case report". Diagnostic Pathology. 6 (84): 84. doi:10.1186/1746-1596-6-84. PMC 3182960. PMID 21929773.
- Biason-Lauber A (2006). The Battle of the Sexes: Human Sex Development and Its Disorders in Molecular Mechanisms of Cell Differentiation in Gonad Development. Results and Problems in Cell Differentiation. 58. pp. 337–382. doi:10.1007/978-3-319-31973-5_13. ISBN 978-3-319-31971-1. PMID 27300185.
- Bashamboo A, McElreavey K (2015). "Human sex-determination and disorders of sex-development (DSD)". Seminars in Cell & Developmental Biology. 45: 77–83. doi:10.1016/j.semcdb.2015.10.030. PMID 26526145.
- Donahoe P, Crawford J, Hendren W (1979). "Mixed Gonadal Dysgenesis, Pathogenesis and Management". Journal of Pediatric Surgery. 14 (3): 287–300. doi:10.1016/s0022-3468(79)80486-8. PMID 480090.
- "Turner Syndrome: Condition Information". Eunice Kennedy Shriver National Institute of Health and Human Development. 2012.
- Saenger P, Bondy A (2014). "Turner Syndrome". Pediatric Endocrinology (4th ed.). pp. 664–696. ISBN 9780323315258.
- Elsheikh M, Dunger D, Conway G, Wass J (2002). "Turners Syndrome in adulthood". Endocrine Reviews. 23 (1): 120–140. doi:10.1210/edrv.23.1.0457. PMID 11844747.
- "Endocrine Disruptors, National Institute of Environmental Health Sciences, 2013".
- Robert S (2010). "Pesticide atrazine can turn male frogs into females". Berkeley News, University of California.
- Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M (2015). "Perspectives in Pediatric Pathology, Chapter 5. Gonadal Dysgenesis". Pediatr. Dev. Pathol. 18 (4): 259–78. doi:10.2350/14-04-1471-PB.1. PMID 25105336. S2CID 20122694.